Tumor necrosis factor-? (TNF?) has potent, direct antiviral activity but has not been exploited as an antiviral therapy because of its systemic toxic effects. We have observed that primary human liver cells and hepatoma cells treated with low levels of TNF? are resistant to infection with the hepatitis C virus (HCV) in vitro. This effect is dependent on TNF? interaction with its receptor and is seen in the absence of detectable IFN? or IFN? gene expression. Sindbis virus, an alphavirus, infects Huh-7 hepatoma cells and is insensitive to TNF? pretreatment. However, TNF? synergizes with IFN? to block Sindbis virus infection. We propose to use state-of-the-art techniques to identify key mediators of TNF?'s antiviral effects alone and in combination with IFN?. We propose three Specific Aims. In the first Aim, we will test the requirements for signal transduction through the major pathways activated by TNF? binding to its receptor, using pharmacologic inhibitors as well as dominant negative regulators of TNF? signal transduction. In the second Aim, we will use novel virological and cell biological tools to define the stages in HCV infection that are inhibited following TNF? treatment. In the third Aim, we will use microarray and next-generation sequencing approaches to define the effects of TNF? on the transcriptome, identify candidate genes that may mediate the development of an antiviral state in TNF?- treated cells, and test the importance of these genes by knockdown and overexpression studies. The long-term goals of this research are to identify specific cellular pathways that mediate TNF?'s antiviral activity, and to determine whether it is possible to isolate these activities from TNF?'s systemic toxic effects.

Public Health Relevance

Hepatitis C virus infection remains a major public health problem and can cause liver cancer and cirrhosis, and is the leading indication for liver transplantation in the United States and Europe. We have found that tumor necrosis factor? (TNF?) can make certain cells resistant to infection with hepatitis C virus as well as Sindbis virus, an alphavirus. However, TNF? is highly toxic and is not suitable as a treatment for viral diseases. We propose to use a variety of techniques to determine how TNF? mediates its antiviral activity with the hope of isolating the antiviral effects of TNF? from its toxic effects.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI089957-05
Application #
8882228
Study Section
Immunity and Host Defense (IHD)
Program Officer
Koshy, Rajen
Project Start
2011-07-27
Project End
2016-07-31
Budget Start
2015-08-01
Budget End
2016-07-31
Support Year
5
Fiscal Year
2015
Total Cost
Indirect Cost
Name
University of Oxford
Department
Type
DUNS #
226694883
City
Oxford
State
Country
United Kingdom
Zip Code
OX1 2JD
Laidlaw, Stephen M; Marukian, Svetlana; Gilmore, Rachel H et al. (2017) Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons. Gastroenterology 153:566-578.e5
Dustin, Lynn B (2017) Innate and Adaptive Immune Responses in Chronic HCV Infection. Curr Drug Targets 18:826-843
Dustin, L B; Bartolini, B; Capobianchi, M R et al. (2016) Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. Clin Microbiol Infect 22:826-832
Laidlaw, Stephen M; Dustin, Lynn B (2014) Interferon lambda: opportunities, risks, and uncertainties in the fight against HCV. Front Immunol 5:545
Dustin, Lynn B; Cashman, Siobhán B; Laidlaw, Stephen M (2014) Immune control and failure in HCV infection--tipping the balance. J Leukoc Biol 96:535-48
Saeed, Mohsan; Scheel, Troels K H; Gottwein, Judith M et al. (2012) Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells. Antimicrob Agents Chemother 56:5365-73
Stegmann, Kerstin A; Björkström, Niklas K; Ciesek, Sandra et al. (2012) Interferon ?-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. J Infect Dis 205:1351-62